What can you do if you’re a biopharmaceutical company whose top-selling drug is seeing rapidly declining sales?
You go on a buying spree—or at least, that’s what this top biotech is doing.
Here’s why the results for shareholders are set to be fantastic.
This post originally appeared at Investors Alley.